GERMANTOWN, Md., May 23, 2024
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a
biopharmaceutical company specializing in the development of
innovative gene and cell therapies to improve the lives of
patients, today announced that the Company will host a webcast on
June 3, 2024 at 6:00 PM CT/7:00 PM
ET following the late-breaking oral presentation of results
from the pivotal study of PRGN-2012 for the treatment of recurrent
respiratory papillomatosis (RRP) at the 2024 American Society of
Clinical Oncology (ASCO) Annual Meeting. The webcast will include
an in-depth review of the PRGN-2012 pivotal data and business
update.
Phase 2 study results will be presented on June 3rd at 8:30 AM CT during ASCO in a presentation titled,
"PRGN-2012, a novel gorilla adenovirus-based immunotherapy,
provides the first treatment that leads to complete and durable
responses in recurrent respiratory papillomatosis patients" by
Scott M. Norberg, DO, Associate Research Physician, Center for
Immuno-Oncology, Center for Cancer Research, National Cancer
Institute and a lead investigator for the PRGN-2012 Phase 2
clinical study.
Participants may register and access the webcast through
Precigen's website in the Events & Presentations section. An
archived recording will be posted to the website following the
event.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a dedicated
discovery and clinical stage biopharmaceutical company advancing
the next generation of gene and cell therapies using precision
technology to target the most urgent and intractable diseases in
our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to
find innovative solutions for affordable biotherapeutics in a
controlled manner. Precigen operates as an innovation engine
progressing a preclinical and clinical pipeline of
well-differentiated therapies toward clinical proof-of-concept and
commercialization. For more information about Precigen, visit
www.precigen.com or follow us on X @Precigen, LinkedIn or
YouTube.
AdenoVerse®
Precigen's AdenoVerse
platform utilizes a library of proprietary adenovectors for the
efficient gene delivery of therapeutic effectors, immunomodulators,
and vaccine antigens designed to modulate the immune system.
Precigen's gorilla adenovectors, part of the AdenoVerse library,
have potentially superior performance characteristics as compared
to current competition. AdenoVerse gene therapies have been shown
to generate high-level and durable antigen-specific T-cell immune
responses as well as an ability to boost these responses via repeat
administration. Superior performance characteristics and high yield
manufacturing of AdenoVerse vectors leveraging
UltraVector® technology allows Precigen to engineer
cutting-edge investigational gene therapies to treat complex
diseases.
AdenoVerse® Clinical
Programs
Precigen's AdenoVerse platform is currently under
clinical investigation in a Phase 1/2 study of PRGN-2009 alone or
in combination with an anti-PDL1/TGF-Beta Trap in patients with
HPV-associated cancers (NCT04432597), a Phase 2 study of PRGN-2009
in combination with pembrolizumab in newly diagnosed patients with
HPV-associated oropharyngeal squamous cell carcinoma (OPSCC)
(NCT05996523), a Phase 2 study of PRGN-2009 in combination with
pembrolizumab in patients with recurrent or metastatic cervical
cancer (NCT06157151), and a Phase 1/2 study of PRGN-2012 in
patients with recurrent respiratory papillomatosis (RRP)
(NCT04724980). PRGN-2012 has been granted Orphan Drug
Designation and Breakthrough Therapy Designation in
patients with RRP by the FDA and Orphan Drug Designation by the
European Commission.
Trademarks
Precigen, AdenoVerse, UltraVector and
Advancing Medicine with Precision are trademarks
of Precigen and/or its affiliates. Other names may be
trademarks of their respective owners.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements
are based upon the Company's current expectations and projections
about future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, discovery programs and related milestones, the promise of
the Company's portfolio of therapies, and in particular its CAR-T
and AdenoVerse therapies. Although management believes that the
plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. The Company has no
obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For further information on potential risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K
and subsequent reports filed with the Securities and Exchange
Commission.
Investor Contact:
Steven M.
Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M.
Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-to-host-a-webcast-on-june-3rd-to-detail-pivotal-study-results-of-prgn-2012-in-recurrent-respiratory-papillomatosis-presented-at-the-2024-asco-annual-meeting-302154722.html
SOURCE Precigen, Inc.